Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Lipigon Pharmaceuticals AB's PB Ratio or its related term are showing as below:
OSTO:LPGO'
s PB Ratio Range Over the Past 10 Years
Min: 0.06 Med: 1.66 Max: 7.02
Current: 0.12
During the past 8 years, Lipigon Pharmaceuticals AB's highest PB Ratio was 7.02. The lowest was 0.06. And the median was 1.66.
OSTO:LPGO's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.925
vs OSTO:LPGO: 0.12
During the past 12 months, Lipigon Pharmaceuticals AB's average Book Value Per Share Growth Rate was -67.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -52.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -58.40% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Lipigon Pharmaceuticals AB was -3.10% per year. The lowest was -68.90% per year. And the median was -46.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Lipigon Pharmaceuticals AB PB Ratio Related Terms
Lipigon Pharmaceuticals AB PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:LPGO vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Lipigon Pharmaceuticals AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipigon Pharmaceuticals AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipigon Pharmaceuticals AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Lipigon Pharmaceuticals AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Lipigon Pharmaceuticals AB (OSTO:LPGO) has a PB Ratio of 0.12 as of Aug. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lipigon Pharmaceuticals AB and its competitors. This is 93% below median its historical median of 1.66. Over the past decade, Lipigon Pharmaceuticals AB's PB Ratio has ranged from 0.06 to 7.02.
Is Lipigon Pharmaceuticals AB's PB Ratio too high?
Lipigon Pharmaceuticals AB's current PB Ratio of 0.12 is 93% below median its 10-year median of 1.66. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 7.02. The Biotechnology industry median PB Ratio is 2.93. Lipigon Pharmaceuticals AB's value of 0.12 is 95.9% below this industry median.
How does Lipigon Pharmaceuticals AB's PB Ratio compare to VRTX and REGN?
Lipigon Pharmaceuticals AB's PB Ratio of 0.12 can be compared against companies in the Biotechnology industry. The industry median PB Ratio is 2.93. Lipigon Pharmaceuticals AB's value of 0.12 is 95.9% below this benchmark. Historically, Lipigon Pharmaceuticals AB's own PB Ratio has ranged from 0.06 to 7.02 over the past decade. While the company's 10-year median is 1.66 vs. the industry median of 2.93, Lipigon Pharmaceuticals AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,216 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lipigon Pharmaceuticals AB's current PB Ratio of 0.12 is 95.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lipigon Pharmaceuticals AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lipigon Pharmaceuticals AB's current PB Ratio is 0.12, which is 93% below median its own 10-year median of 1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipigon Pharmaceuticals AB stock overvalued right now?
Lipigon Pharmaceuticals AB (OSTO:LPGO) has a current PB Ratio of 0.12. The stock's GF Value™ is kr0.02, compared to a current price of kr0.00 — trading 92.5% below its estimated fair value. The current PB Ratio is 0.12, which is 93% below median its 10-year median of 1.66 and 95.9% below the Biotechnology industry median of 2.93. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Lipigon Pharmaceuticals AB (OSTO:LPGO), the current PB Ratio is 0.12 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:LPGO has been successfully added to your 
